AI
Tuesday, July 30, 2019 11:43:25 PM
Ocular Therapeutix , Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
SHORT INTEREST
8.24M 07/15/19
P/E Current
-2.78
P/E Ratio (with extraordinary items)
-2.92
Average Recommendation: OVERWEIGHT
Average Target Price: 9.67
Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!
IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Recent OCUL News
FEATURED Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 • Mar 10, 2025 9:05 AM
North Bay Resources Announces Assays up to 5.69% Copper, 1 Opt. Silver, and 0.22% Vanadium at Copper Island Project, British Columbia • NBRI • Mar 10, 2025 9:00 AM
Avant Technologies and JV Partner, Ainnova, Strategically Align with Apollo Hospitals to Advance AI in Healthcare • AVAI • Mar 10, 2025 8:00 AM
Veri Medtech (VRHI) Network Grows To 400 Physicians • VRHI • Mar 10, 2025 7:32 AM
One World Products' Isiah Thomas Issues Investor Update • OWPC • Mar 6, 2025 9:19 AM
Authentic Holdings To Reduce Debt by over $2 Million While Achieving Substantial Revenue Growth • AHRO • Mar 6, 2025 8:00 AM
